Delivery Order SPE2DB24D2105-SPE2DB25FAQDR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,148.98 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price contract with no set-aside designation, classified as a competitive delivery order under the company's broader pharmaceutical supply agreements. Performance will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 14,...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $3,431.61 on August 21, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed-price, non-set-aside delivery order is scheduled for completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under AmerisourceBergen's larger relationship...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.88 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 14, 2025. The contract is classified as firm fixed price with an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the company's capability to meet...
- The Defense Logistics Agency (DLA) awarded a $36,746.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectables. The contract, which represents a child order under a larger indefinite delivery vehicle, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This award was competitively awarded with no set-aside...
- The U.S. Defense Department's Medical Supply Chain awarded a $3,447.09 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 8, 2025, with completion targeted for August 11, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999.999 billion through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections with a ceiling value of $3,648.19. This firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside designation and represents a routine pharmaceutical supply transaction under the...
- The Defense Logistics Agency awarded a $25,617.61 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections. This is a firm fixed price, competitively awarded contract with an ultimate completion date of July 23, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,143.87 for Zepbound 10 mg/0.5 mL pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed price delivery order issued under AmerisourceBergen's broader pharmaceutical supply arrangement with DLA. The place of performance is listed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $19,662.17 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections. This is a firm fixed price, competitively awarded contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections valued at $7,625.80 on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price, non-set-aside delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single-line pharmaceutical supply delivery under a competitive procurement process, reflecting the agency's continued...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQDRDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,588.32 on September 2, 2025, for Zepbound 7.5 mg/0.5 mL pen injections. This is a firm fixed-price delivery order with no set-aside designation, issued as a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX). The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with a completion deadline of September 3, 2025. This delivery order represents a routine pharmaceutical procurement supporting the Defense Health Agency and other federal healthcare systems. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, supplies a comprehensive range of medications and medical supplies through its $999.99 billion prime IDV with DLA running through December 2026. The company's federal contract portfolio demonstrates extensive capability in delivering both brand-name and generic pharmaceuticals across multiple therapeutic domains, positioning it as a key provider for military and veteran healthcare supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 9/2/25 |